Hypoxia, a hallmark of solid tumors, determines the selection of invasive and aggressive
malignant clones displaying resistance to radiotherapy, conventional chemotherapy or …

Standard-of-care management of renal cell carcinoma (RCC) indisputably relies on surgery
for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease …

Immune checkpoint inhibitors (ICIs) in combination with vascular endothelial growth factor
receptor (VEGFR) tyrosine kinase inhibitors (TKIs) have become a new standard of care in …

While many patients with non-metastatic renal cell carcinoma (RCC) can be cured with
surgery alone, upward of 40% of patients recur in a short delay, raising the question of …

Objective The treatment landscape for renal cell carcinoma (RCC) is rapidly evolving. The
aim of this review is to summarize the randomized-controlled trials evaluating the role of …

Simple Summary Checkpoint inhibitors and anti-angiogenic therapies are treatments that
slow the progression of renal cell carcinoma, the most common type of kidney cancer …

Immunotherapy offers deep and durable disease control to some patients, but many tumors
do not respond to treatment with single-agent immune checkpoint inhibitors (ICIs). One …

Perioperative therapy in renal cancer in the era of immune c... : Current Opinion in Urology
Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy : Current …

Immune checkpoint blockade (ICB) is the foundation of current first‐line therapies in patients
with metastatic renal cell carcinoma (mRCC) with the potential for eliciting long‐lasting …

Results: Two (40%) had a reduction in IVC TT based on the Mayo Classification. Tumor
thrombus volume reduction was seen in all patients (100%). Four of 5 patients (80%) were …